10 July 2019

To: Recipients of M100, 29th ed.
From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality
Subject: Revisions to Definitions

This notice is intended to inform users of revisions to two definitions in the Instructions for Use of Tables in CLSI document M100, Performance Standards for Antimicrobial Susceptibility Testing, 29th ed. The revisions are shown below as highlighted and/or stricken text.

**susceptible-dose dependent (SDD)** - a category defined by a breakpoint that implies that susceptibility of an isolate depends on the dosing regimen that is used in the patient. To achieve levels that are likely to be clinically effective against isolates for which the susceptibility testing results (either minimal inhibitory concentrations [MICs] or zone diameters) are in the SDD category, it is necessary to use a dosing regimen (ie, higher doses, more frequent doses, or both) that results in higher drug exposure than that achieved with the dose that was used to establish the susceptible breakpoint. Consideration should be given to the maximum, literature-supported dosage regimens, because higher exposure gives the highest probability of adequate coverage of an SDD isolate. Appendix E lists the doses used when establishing SDD categories. The drug label should be consulted for recommended doses and adjustment for organ function; **NOTE:** The concept of SDD has been included within the intermediate category definition for antimicrobial agents. However, this is often overlooked or not understood by clinicians and microbiologists when an intermediate result is reported. The SDD category may be assigned when doses well above those used to calculate the susceptible breakpoint are supported by the literature, widely used clinically, and/or approved and for which sufficient data to justify the designation exist and have been reviewed. The SDD category also includes a buffer zone for inherent variability in test methods, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations, especially for drugs with narrow pharmacotoxicity margins. When the intermediate category is used, its definition remains unchanged. **See Appendix F for additional information.**

**intermediate (I)** - a category defined by a breakpoint that includes isolates with MICs or zone diameters within the intermediate range that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates; **NOTE:** The intermediate category implies clinical efficacy in body sites where the drugs are physiologically concentrated or when a higher-than-normal dosage of a drug can be used. This category also includes a buffer zone for inherent variability in test methods, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations, especially for drugs with narrow pharmacotoxicity margins.
Please note, Tables 2 will be revised in M100, 30th ed. to appropriately indicate agents that have the potential to concentrate at an anatomical site. This information will also be included in the “intermediate” definition's NOTE (eg, “NOTE: The intermediate category implies clinical efficacy in body sites where the drugs are physiologically concentrated. Agents in Tables 2 that have the potential to concentrate at an anatomical site are indicated. The intermediate category also includes a buffer zone for inherent variability in test methods, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations, especially for drugs with narrow pharmacotoxicity margins.).

If you require any additional clarification regarding these revisions, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.
M100
Performance Standards for Antimicrobial Susceptibility Testing

This document includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02, M07, and M11.

A CLSI supplement for global application.
Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

**Consensus Process**

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

**Commenting on Documents**

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

**Appeal Process**

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

**Get Involved—Volunteer!**

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
*standard@clsi.org*
Performance Standards for Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD
Jean B. Patel, PhD, D(ABMM)
April M. Bobenchik, PhD, D(ABMM)
Shelley Campeau, PhD, D(ABMM)
Sharon K. Cullen, BS, RAC
Marcelo F. Galas
Howard Gold, MD, FIDSA
Romney M. Humphries, PhD, D(ABMM)
Thomas J. Kirn, Jr., MD, PhD

James S. Lewis II, PharmD, FIDSA
Brandi Limbago, PhD
Amy J. Mathers, MD, D(ABMM)
Tony Mazzulli, MD, FACP, FRCP(C)
Sandra S. Richter, MD, D(ABMM), FCAP, FIDSA
Michael Satlin, MD, MS
Audrey N. Schuetz, MD, MPH, D(ABMM)
Jana M. Swenson, MMSc
Pranita D. Tamma, MD, MHS

Abstract

The data in the tables are valid only if the methodologies in CLSI documents M02, M07, and M11 are followed. These standards contain information about disk diffusion (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02, M07, and M11. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.